Daniel N. Swisher, Jr
2016 - Sunesis Pharmaceuticals
In 2016, Daniel N. Swisher, Jr earned a total compensation of $1.5M as CEO and President at Sunesis Pharmaceuticals, a 25% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $255,000 |
|---|---|
| Option Awards | $772,752 |
| Salary | $513,125 |
| Other | $3,466 |
| Total | $1,544,343 |
Swisher received $772.8K in option awards, accounting for 50% of the total pay in 2016.
Swisher also received $255K in non-equity incentive plan, $513.1K in salary and $3.5K in other compensation.
Rankings
In 2016, Daniel N. Swisher, Jr's compensation ranked 6,103rd out of 14,075 executives tracked by ExecPay. In other words, Swisher earned more than 56.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,103 out of 14,075 | 57th |
Division Manufacturing | 2,228 out of 5,488 | 59th |
Major group Chemicals And Allied Products | 731 out of 1,900 | 62nd |
Industry group Drugs | 552 out of 1,543 | 64th |
Industry Pharmaceutical Preparations | 432 out of 1,173 | 63rd |
Source: SEC filing on April 20, 2017.
Swisher's colleagues
We found one more compensation record of an executive who worked with Daniel N. Swisher, Jr at Sunesis Pharmaceuticals in 2016.
2016
Eric Bjerkholt
Sunesis Pharmaceuticals
Chief Financial Officer
News
Jazz Pharmaceuticals CEO Bruce Cozadd's 2021 pay jumps 25% to $16M
June 10, 2022
Jazz Pharmaceuticals CEO Bruce Cozadd's 2020 pay slips 15% to $13M
June 11, 2021
Jazz Pharmaceuticals CEO Bruce Cozadd's 2019 pay jumps 29% to $15M
June 12, 2020
Jazz Pharmaceuticals CEO Bruce Cozadd's 2018 pay rises 11% to $11M
June 14, 2019